AI
| Followers | 843 |
| Posts | 122988 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Sunday, January 27, 2008 7:29:43 PM
Re: FLML
>somewhere below locteron (since we haven't seen the full VL data yet), but above "the other interferons", since there is positive top line data in a comparator clinical trial vs pegylated interferon<
In reviewing FLML’s PR from October, it seems that all we have is the company’s assurance that the top-line data were positive (#msg-24008801). Therefore, I think I’ll put IFN-alpha-XL in the same group with Albuferon and IFN-Lambda. Feel free to argue for a different placement
>somewhere below locteron (since we haven't seen the full VL data yet), but above "the other interferons", since there is positive top line data in a comparator clinical trial vs pegylated interferon<
In reviewing FLML’s PR from October, it seems that all we have is the company’s assurance that the top-line data were positive (#msg-24008801). Therefore, I think I’ll put IFN-alpha-XL in the same group with Albuferon and IFN-Lambda. Feel free to argue for a different placement
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
